8-K: Catheter Precision Stockholders Approve 1-for-19 Reverse Split and Key Share Issuances

Catheter Precision, Inc. stockholders approved a 1-for-19 reverse stock split to maintain NYSE American listing, alongside authorizations for significant share issuances related to warrants and convertible preferred stock.

Summary

• Stockholders approved a 1-for-19 reverse stock split, effective August 15, 2025, to meet NYSE American minimum bid price requirements.
• The reverse split will reduce outstanding common shares from approximately 23.3 million to 1.2 million.
• Fractional shares resulting from the split will be settled in cash.
• Stockholders approved the issuance of up to 4,285,716 shares upon exercise of Series L Common Stock Purchase Warrants.
• Stockholders approved the issuance of up to 8,574,000 shares upon conversion of Series B Convertible Preferred Stock.
• Stockholders approved the issuance of up to 257,143 shares upon exercise of 2025 Placement Agent Common Stock Purchase Warrants.
• Martin Colombatto was elected as a Class I director to serve a three-year term.
• The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for fiscal year 2025 was ratified.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to the necessity of a severe reverse stock split (1-for-19) to maintain exchange listing, indicating significant share price underperformance and potential financial distress. While shareholder approvals for capital structure adjustments are positive for management's plans, they are often reactive measures to underlying issues.

Positives

• Stockholders approved all six proposals, indicating support for management's strategic initiatives.
• Approval of the reverse stock split is a necessary step to maintain compliance with NYSE American listing requirements, potentially preventing de-listing.
• Approval of share issuances for warrants and convertible preferred stock facilitates potential capital conversion and exercise.

Negatives

• The necessity of a 1-for-19 reverse stock split indicates the company's stock price is significantly below the NYSE American minimum bid price requirement, signaling financial distress or poor market performance.
• A reverse stock split can sometimes lead to decreased liquidity and further price declines.
• The low voter turnout (46.1% of outstanding shares represented) might indicate a lack of strong shareholder engagement.

Risks

• The reverse stock split may not have the desired effect of maintaining the minimum bid price requirement.
• Inability to maintain compliance with NYSE American listing requirements could lead to de-listing.
• The reverse stock split and related post-split trading could be delayed or indefinitely postponed.
• General risks impacting the business as detailed in the company's Form 10-K for the year ended December 31, 2024.

Future Outlook

The company aims to maintain compliance with NYSE American's continued listing requirements through the reverse stock split. The timing of the reverse stock split is set for August 15, 2025.

Management Comments

• The reverse stock split is being implemented to ensure that the Company continues to meet the minimum bid price requirement for continued listing on the NYSE American, its current exchange.

Industry Context

The need for a reverse stock split to maintain exchange listing is common for smaller, often struggling, companies in various industries, including medical devices. It reflects challenges in maintaining investor confidence and market valuation. The approval of share issuances for warrants and convertible preferred stock suggests ongoing efforts to manage capital structure and potentially raise funds, which is typical for growth-stage or financially constrained companies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders will experience a significant reduction in the number of shares held (19-for-1 consolidation) but their percentage ownership will remain largely unchanged (except for cash settlement of fractional shares). The primary impact is the attempt to maintain NYSE American listing, which could prevent de-listing and preserve liquidity. However, reverse splits often precede further price declines.

Next Steps

• The company will file a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect the reverse stock split.
• The 1-for-19 reverse stock split will become effective as of 12:01 a.m. (Eastern Time) on August 15, 2025.
• The company's common stock is expected to begin trading on a split-adjusted basis when the market opens on August 15, 2025.

Key Dates

Recommendation

The necessity of a severe 1-for-19 reverse stock split to maintain exchange listing is a strong negative signal, indicating significant underlying issues with the company's valuation and potentially its operational performance. While the split aims to prevent de-listing, reverse splits often fail to sustain higher prices and can lead to further declines due to negative market perception, reduced liquidity, and a lack of fundamental improvement. The approval of share issuances for warrants and convertible preferred stock, while necessary for capital structure management, also points to ongoing dilution potential. For a seasoned investor, this filing suggests a company in distress, making it a "sell" to avoid further potential losses.

Keywords

Catheter Precision, VTAK, Reverse Stock Split, NYSE American, Shareholder Meeting, Corporate Governance, Stock Issuance, Warrants, Convertible Preferred Stock, Listing Requirements, Medical Devices, Healthcare